September has brought great recognition to several of our colleagues.
We are delighted to announce professors Aubert, Ni and Tsao at the Department of Laboratory Medicine and Pathobiology (LMP) have received distinguished honours.
“Seeing our colleagues receive such honours this month has been rewarding on so many levels. It makes me incredibly proud to be part of a department that achieves such transformational work, with direct impact on clinical care. Each of our colleagues has earned this recognition for their hard work, dedication, collaborative nature and drive to improve the health of all Canadians, and beyond.” Dr Rita Kandel, Chair of LMP.
Professor Isabelle Aubert, Senior Scientist in Biological Sciences at Sunnybrook Research Institute (SRI), has been recognized with a Tier 1 Canada Research Chair (CRC) in Brain Repair and Regeneration.
The funding will help Dr Aubert and her team to develop therapies to stop neurodegeneration and promote regeneration in cases of Alzheimer's disease, a focus of her research.
Dr Aubert commented “I am very fortunate to work with bright and wonderful people in my lab, at Sunnybrook, at U of T, across Canada and around the globe. I am a strong advocate of excellence — scientific and otherwise — through teamwork. Research and discovery, and anything that we do, can be enhanced by our collective knowledge, expertise and creativity. I am thrilled to receive a CRC and feel honoured that our research has been recognized.”
Professor Heyu Ni, also a Platform Director at Unity Health Toronto, St. Michael’s Hospital, and Senior Scientist of Canadian Blood Services Centre for Innovation, has been elected as a Fellow of the Canadian Academy of Health Sciences (CAHS).
CAHS Fellows are nominated by their peers and selected based on their internationally recognized leadership, academic performance, scientific creativity and willingness to serve. This recognises Dr Ni’s significant and world-leading contribution to his field, and the health of Canadians.
Dr Ni’s research investigates the role(s) of adhesion molecules involved in clot formation as well as their implications for hemostasis (including bleeding disorders) and thrombotic diseases (ie. heart attack and stroke).
He commented to the Canadian Blood Services, “I feel [it is a] great honour that my work has been highly respected. This Fellowship will enhance my opportunities to communicate with government and policy makers to improve our health policy to better service Canadians as well as patients worldwide.”
Professor Ming-Sound Tsao, a Consultant Thoracic Pathologist and Senior Scientist at the Princess Margaret Cancer Centre, University Health Network, has been appointed Fellow of The Royal Society of Canada.
Professor Rama Khokha, jointly appointed with Medical Biophysics, also became a Fellow.
The Fellowship is a recognition awarded to the country’s most distinguished scholars, artists and scientists who, according to the RSC, have "made remarkable contributions in the arts, the humanities and the sciences, as well as in Canadian public life".
Dr Tsao said, “I am thrilled by my election to join the Fellowship of the Royal Society of Canada. This honour partly reflects the power of team science and collective efforts of my collaborators and people in my lab, especially trainees. I feel very fortunate to be part of the generation that is revolutionizing the treatment of cancer patients with precision medicine based on molecular biomarkers and targets. I also hope this honour may inspire more pathologists to become leaders in translating scientific discoveries into knowledge and clinical practice that benefit patients to improve their survival and quality of life.”
Dr. Tsao’s research understands molecular abnormalities in lung cancers to improve the accuracy of diagnosis and treatment. His work has contributed to the molecular characterization of lung cancer and has identified molecular biomarkers for selecting patients to receive targeted anti-cancer drugs. Dr. Tsao’s laboratory has also pioneered the establishment and characterization of patient-derived tumour models for lung and pancreatic cancers.